HOME >> MEDICINE >> NEWS
Common drug, given promptly, reduces incidence of post-traumatic stress disorder, small study finds

A common drug administered in the first hours following trauma to patients deemed to be at risk of developing post-traumatic stress disorder (PTSD) reduced the occurrence of PTSD, according to a study led by researchers at the University of Lille, France.

While the study involved a small number of subjects, its results are encouraging, says its senior author, Charles Marmar, MD, associate chief of staff for mental health at the San Francisco VA Medical Center and professor and vice chair of psychiatry at University of California, San Francisco.

"The study is based on the new theory that PTSD is most likely to occur in patients who experience a particularly severe and prolonged response to trauma. If this model proves accurate after five or ten replications of studies like this one, it could have very profound ramifications. From a public health perspective, if you could identify the subgroup of people who are susceptible to PTSD, giving them this course of medication -- which is brief, very well tolerated and inexpensive -- could be very effective prevention [following major trauma] and may have great social relevance." The study appears in the November 1 issue of Biological Psychiatry.

All people confronted by a life-threatening situation, such as a car accident or physical assault, react by releasing a rush of stress hormones, including adrenalin and noradrenalin, which are produced in the adrenal glands, located atop the kidneys. This response, known as "adrenergic activation," initiates the reactions that quicken the heart rate, constrict the vasculature to prevent bleeding to death, and provide energy to the muscles, priming the body to "fight, flee, or freeze." The hormonal flood also strengthens the brain's ability to form and retain emotional memories. The longer the duration of the adrenergic activation, the more vivid and tenacious are the memories of the event. In most people, after minutes to hours the reaction begins to subside.
'"/>

Contact: Liese Greensfelder
lgreensfelder@pubaff.ucsf.edu
415-476-8429
University of California - San Francisco
22-Oct-2003


Page: 1 2 3 4 5

Related medicine news :

1. Common anesthetics appear safe for developing fetal brain
2. Common schizophrenia symptoms often overlooked by physicians, according to expert panel
3. Common antidepressants lower effects of tamoxifen in many women
4. Common antidepressant may affect youths bone development
5. Common epilepsy treatment to be used for bulimia nervosa
6. Mouth sores: Common complaints of students
7. New Commonwealth Fund analysis compares candidtes health care reform proposals
8. Common heart surgery potentially dangerous
9. Common treatment for cancer pain stimulates breast tumor growth in mice
10. Common diabetes drug causes arteries to spasm, endangering heart
11. Commonly prescribed antibiotic ineffective for treating bronchitis

Post Your Comments:
(Date:6/19/2013)... NC (PRWEB) June 19, 2013 ... Inc., announced organizational changes to advance development of ... Mowell said, “To support the advanced development of ... made changes to the Company’s management structure and ... , The Company announced that Michael Galiger will ...
(Date:6/19/2013)... Brightree LLC , the leading provider of ... post-acute care industry, has been ranked for the first time ... 100 (HCI 100) list. This prestigious list features the ... of revenue during the last fiscal year. Since 2005, Brightree’s ... and the company has built its organization to more than ...
(Date:6/19/2013)... Many trying-to-conceive couples seek medical intervention ... to a recent study published in ... of this research confirm what Fairhaven Health has ... that trying-to-conceive women would benefit from tracking ovulation, ... Fairhaven Health is a leading provider of ovulation ...
(Date:6/19/2013)... vaccination, polio has been pushed to the brink of extinction ... one of the big questions which a Bristol academic addresses ... Williams, Professor of Medicine at the University of Bristol, has ... years. Paralysed with fear: the story of polio explores the ... the history of the disease. , According to ...
(Date:6/19/2013)... Boston, MA (PRWEB) June 19, 2013 ... Productions , a premier kids entertainment media organization, ... Massachusetts-based serious games company, will be introducing the ... game, StudenTopia. The 3D game is geared toward ... healthy eating and active lifestyles by rewarding positive ...
Breaking Medicine News(10 mins):Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 2Health News:Entegrion Announces Organizational Changes to Support Advanced Product Development 3Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4Health News:Paralysed with fear: The story of polio 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 4Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 5
(Date:6/19/2013)... Pharma IQ is pleased to announce ... of the results from an industry survey conducted earlier this ... that CROs would be an area of active investment in ... 6 or more clinical trials in the BRIC region. The ... USA Summit explores the latest trends, challenges ...
(Date:6/18/2013)... 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ... development and commercialization of novel bile acid therapeutics to ... an underwritten public offering of 1,730,000 shares of its ... per share.  In addition, Intercept has granted the underwriters ... 259,500 shares of common stock. All of ...
(Date:6/18/2013)... Royal Philips (NYSE: PHG, AEX: ... Leader in Imaging Equipment in the 2013 Best in ... received Best in KLAS and Best in Category awards ... Computed Tomography (CT), Ingenia 1.5T and 3.0T Magnetic ... annual Best in KLAS Awards: Medical Imaging & Infrastructure ...
Breaking Medicine Technology:Pharma IQ Presents the Latest Trends in Clinical Trial Supply 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS 2
Cached News: